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ABSTRACT 
Objective: The purpose of this paper is to develop and validate a LC-MS/MS method for the quantification of gemcitabine in whole human blood 
using dried blood spots. 
Methods: Gemcitabine fortified blood samples without tetrahydrouridine were spotted (50 µl) onto the DBS cards and dried for 2h at ambient room 
temperature. 3 mm punched spots were extracted by acetonitrile: water (90:10v/v) containing carbamazepine as internal standard (IS). Analyte 
and IS were separated on BDS Hypersil C18,(100 X 4.6 mm, 5 µ) column using a mixture of methanol and 2 mM ammonium acetate buffer (65:35 
v/v) at a flow rate of 0.5 mL/min. Detection involved API-4000 LC-MS/MS with electrospray ionization in the positive ion mode. 
Results: The assay was validated over the concentration range of 5-5000 ng/ml. Intra and inters assay precision values (% CV) were less than 6.0% 
while the accuracy was within±15%. The mean recovery (%CV) of gemcitabine from DBS was ≥83.5% (≤4.0). Hematocrit values ranging between 
0.25 and 0.62 were within acceptable limit with accuracy 93.0-103.1% of nominal values and %CV of ≤ 6.5 across the LQC and HQC levels. 
Gemcitabine was stable on DBS cards for atleast 90days at room temperature.  
Conclusions: A cytidine drug like gemcitabine exhibits ex vivo instability and rapidly converts to inactive metabolite in blood. All current published 
methods for stabilisation include tetrahydrouridine a cytidine deaminase inhibitor in the sample collection tubes. The proposed DBS method can be 
used as an alternative assay to conventional plasma analysis without adding enzyme inhibitor. 
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INTRODUCTION 
Pancreas cancer is the fourth commonest cause of cancer-related 
mortality across the world, with incidence equalling mortality [1]. 
Untreated metastatic pancreatic cancer has a median survival of 3–5 
months and 6–10 months for locally advanced disease [2]. The 
majority of cases are diagnosed in the advanced stages, making 
curative therapy impossible and leading to poor prognosis [3]. 
Gemcitabine (2, 2-difluoro-2-deoxycytidine, dFdC) is a novel 
deoxycytidine analog [4] administered as the intravenous infusion 
to treat human malignancies including pancreatic [5], ovarian [6], 
breast [7] and bladder [8). By deoxycytidine kinase, gemcitabine 
phosphorylates intracellularly to an active metabolites 2, 2-
diXuorodeoxycytidine-5_-diphosphate (dFdCDP) and triphosphate 
(dFdCTP) inhibiting the processes required for DNA synthesis. 
Incorporation of dFdCTP into DNA is most likely the major 
mechanism by which gemcitabine causes cell death. [9] Gemcitabine 
is metabolically inactivated by cytidine deaminase (CDA) into the 
metabolite 2, 2-diXuorodeoxyuridine (dFdU) [10]. Several analytical 
methods have been proposed for the measurement of gemcitabine in 
plasma/serum or tissues. Most commonly used methods were HPLC-
UV [11-17] with a run time of more than 20 mins and require a 
minimum plasma volume of 200 µl with a detection limit range 
between 0.1 to 2.6µg/ml. HPLC coupled to mass spectrometric 
detection offers a wide range of advantages in support of bio analysis 
in terms of selectivity, sensitivity and faster analysis time. The 
published LC-MS/MS methods use a high volume of plasma [18, 19] or 
few had very long run time exceeding 15 min [20-22]. A method 
proposed by Bowen c, et al. [23] with a very short run time of 1.7 min 
involves a complicated derivatisation process of gemcitabine with 
dansyl chloride to retain it on the reverse phase column.  
Dried blood spot (DBS) screening has been used as an alternative 
sample collection for pediatric purposes in 1960s [24]. DBS analysis 
provides several advantages, including reduced blood sample 
volumes collected for drug analysis and ease of collection, storage, 
and transportation [25, 26]. Additionally, DBS sample preparation, 
stability, and storage are usually most convenient and been 
successfully applied for analysing small molecules in different 
therapeutics areas like anti-malarials [27, 28] anti-retrovirals [29-
31] and many more. Moreover, some compounds are unstable ex-
vivo in biological fluids (e. g., blood or plasma) and require adapted 
procedures to prevent degradation [32, 33] in such cases; stability 
can be enhanced on DBS without the need for the aforementioned 
procedures [34, 35]. The objective of this method was to develop an 
alternative assay for stabilisation of gemcitabine avoiding addition 
of enzyme inhibitors and thus potentially minimising the errors in 
clinic in sample collection and also eliminating biohazard risks. 
MATERIALS AND METHODS  
Chemicals and materials 
Gemcitabine hydrochloride reference sample (99.8% pure) was 
obtained from USP Reference Standard. Carbamazepine (99.24% 
pure) was used as an internal standard and was obtained from 
Clearsynth Labs (P) Ltd (Mumbai, India). Their chemical structures 
were shown in fig. 1. HPLC grade methanol and acetonitrile were 
purchased from JT Baker (Phillipsburg, USA). Analytical grade 
ammonium acetate was purchased from Merck Ltd (Mumbai, India). 
Tetrahydrouridine was purchased from Calbiochem (San Diego,USA). 
Water used for the LC–MS/MS analysis was prepared by using Milli Q 
water purification system procured from Millipore (Bangalore, India). 
FTA DMPK-A cards and Harris Uni-Core Punch, 3 mm were purchased 
from GE healthcare. The control human whole blood was procured 
from Deccan’s Pathological Lab’s (Hyderabad, India). 
LC–MS/MS instrument and conditions 
An HPLC system (Shimadzu, Kyoto, Japan) consisting of a binary LC–
20AD prominence pump, an auto sampler (SIL–HTc) and a solvent 
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degasser (DGU–20A3) was used for the study. Aliquot of 10 µl of the 
extracted samples were injected onto the column, BDS Hypersil C18, 
(100 X 4.6 mm, 5 µ), which was kept at 40 ºC. An isocratic mobile 
phase consisting of a mixture of methanol and 2 mM ammonium 
acetate buffer (65:35 v/v) at a flow rate of 0.5 mL/min was used to 
separate the analyte from the endogenous components. Detection 
was carried out in the positive electospray ionisation mode for the 
analyte and the IS using an AB Sciex API–4000 mass spectrometer 
(Foster City, CA, USA) equipped with a Turboion spray ™ interface at 
500 ºC. The ion spray voltage was set at 5500 V. The source 
parameters viz. the nebulizer gas (GS1), auxiliary gas (GS2), curtain 
gas and CAD were set at 45, 55, 20, and 6 psi, respectively. The 
compound parameters viz. declustering potential (DP) 45V for 
gemcitabine and 25V for carbamazepine, collision energy and 
collision cell exit potential were 25 V and 12v for both gemcitabine 
and carbamazepine. Detection of the ions was carried out in the 
multiple–reaction monitoring mode (MRM), by monitoring the 
transition pairs of m/z 264.2 precursor ion to the m/z 112.0 product 
ion for gemcitabine and m/z 237.3 precursor ion to the m/z 194.1 
product ion for carbamazepine. Both Q1 and Q3 Quadrupoles were 




a) Gemcitabine b) Carbamazepine 
Fig. 1: Chemical Structures of Gemcitabine and Carbamazepine 
 
Preparation of stock solutions of the analyte and IS 
Two different sets of primary stock solutions for gemcitabine were 
prepared by separate weighing, to get at a concentration of 1 mg/ml 
in water and were stored at 2-8 °C for their stability. Each set of 
primary stock solutions was suitably diluted with Water for the 
preparation of working standard solutions of calibration curve (CC) 
and quality control (QC) samples. A working IS dilution (4000 
ng/ml) was prepared from the IS stock (methanol) 1 mg/ml in 
acetonitrile: water (90:10v/v). 
Preparation of calibration curve standards and quality control 
samples 
Calibration samples of gemcitabine were prepared at concentration 
levels of 5.0, 12.5, 25.0, 50.0, 125.0, 250.0, 1250.0, 2500.0, 4000.0 
and 5000.0 ng/ml as a single batch at each concentration levels. 
Similarly, quality control (QC) samples were also prepared as a bulk 
based on an independent weighing of standard drug, at 
concentrations of 5.2 (LLOQ), 14.5 (low), 241.5 (middle 1), 1050.0 
(middle 2) and 4200 ng/ml (high) as a single batch at each 
concentration. Both calibration standards and Quality control 
samples were prepared in human K2 EDTA blood. The final 
hematocrit in the prepared calibration standards and QC samples 
were about 0.435. A 50 µl aliquot of each calibration standard and 
QC sample was spotted onto the DBS cards. The cards were left on 
the bench at ambient room temperature for a minimum of 2h for 
complete drying of blood spots and then packed in a sealed plastic 
bag with small amount of desiccant. 
Effect of tetrahydrouridine: plasma versus whole blood (dried 
blood spots) 
Whole blood stability of gemcitabine in the presence and 
absence of cytidine deaminase inhibitor 
In brief, the experiment was designed by spiking a known 
concentration at (HQC Level) separately into whole human blood in 
presence of THU (positive control) and in absence of THU (negative 
control). The spiked samples were left at room temperature and 
aliquots were removed at time points 0.00, 0.25, 0.5, 0.75, 1, 2, 3, 4, 
6, 8, and 24h from both control samples. Plasma was isolated by 
centrifugation at 1500g for 5 min and then frozen at-20o
From the literature, recommended analytical methods [11-23] for 
the analysis of gemcitabine tetrahydrouridine a cytidine deaminase 
inhibitor must be added to the sample collection tubes prior to 
sample collection to prevent deamination of gemcitabine to inactive 
metabolite dFdU. A series of THU concentrations ranging from 1µg 
to 100µg was evaluated and a final concentration of 25µg/ml of THU 
was optimized in-house to inhibit the deamination activity. 
Short term and long term stability of gemcitabine in presence 
and absence of THU on DBS cards 
c. The 
concentration of gemcitabine in plasma samples was determined as 
described below in sample extraction. 
In parallel to the above experiment, a similar experiment was 
carried out by spiking gemcitabine at a concentration of LQC and 
HQC into pre-treated whole human blood with THU. 50 µl of the 
above was spotted onto the DBS cards (~60 spots were prepared at 
each level) and dried at room temperature for 2hr. An equal 
concentration of gemcitabine was spiked into whole human blood 
without THU at the same time. This was also spotted onto the fresh 
DBS cards (50 µl). 
Sample extraction 
A 3-mm disc was punched from each dried blood spot sample using 
Harris Uni-Core Punch and transferred to individual 1.5 ml 
eppendorf tubes. 200 µl of IS working solution (4000 ng/ml) was 
added to all samples, except matrix blanks to which 200 µl aliquot of 
acetonitrile/water (90/10, v/v) was added. The tubes were capped 
tightly and gently mixed for 20 minutes on Vortexer (Eppendorf 
mixmate) and then centrifuged at 14000g for 5 min. Finally 100 µl of 
each extract was transferred to HPLC vials and 10 µl aliquot of it was 
injected on to the column. The same procedure was followed for 
plasma samples by separating 50 µl of plasma from spiked whole 
human blood with gemcitabine to assess the stability studies in the 
presence and absence of THF. 
Method validation 
Although there is no specific regulatory guidelines exist for the 
validation of bioanalytical methods using DBS cards. The entire 
validation of the method was carried out as per FDA guidelines [36] 
(Bioanalytical Method Validation published in May 2001). The 
method was validated for various parameters like selectivity, 
sensitivity, matrix effect, linearity, precision, accuracy, recovery, 
dilution integrity, stability and also some additional experiments 
unique to DBS including spotting volume, and hematocrit were 
evaluated. Selectivity of the method was assessed by analyzing six 
different lots of blank human blood for interference at the retention 
time of gemcitabine and it’s IS. The area responses of the interfering 
substances or noise at the retention times of the gemcitabine and IS 
were acceptable, if the % interference was less than 20% of the 
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mean response of the lowest standard in calibration curve point or 
LLOQ (n = 6). The area responses of the interfering substances or 
noise at the retention time of internal standard were acceptable, if 
the % interference was less than 5 % mean response of the internal 
standard areas in the 6 LLOQ samples. 
Sensitivity was carried out by the noise or the response from six 
spiked LLOQ samples. The six replicates should have a precision of ≤ 
20% and with an accuracy of±20% of the nominal value of the LLOQ. 
Matrix effect, expressed as IS normalized matrix factor (MF) was 
assessed by comparing the mean area response of post–extraction 
spiked samples with the mean area of aqueous samples (neat 
samples) prepared in mobile phase solutions at LQC and HQC levels. 
The overall precision of the matrix factor was expressed as 
coefficient of variation (CV). 
 
Matrix effect was also evaluated with six different lots of human 
blood. Three replicate samples each of LQC and HQC were prepared 
from different lots of blood (36 QC samples in total). 
The linearity of the method was determined for gemcitabine in the 
concentration range of 5-5000 ng/ml. As per the guidelines for the 
determination of linearity, a calibration curve should consist of a 
blank sample (matrix sample processed without analyte or internal 
standard), a zero sample (matrix sample processed without analyte 
but with internal standard), and at least six non-zero samples 
(matrix samples processed with analyte and internal standard) 
covering the expected range, including LLOQ.  
The acceptance limit of accuracy for each of the back calculated 
concentration was±15% of their nominal values except LLOQ which 
it was±20% of the LLOQ concentration. For a calibration curve to be 
accepted at least 67% of nonzero standards should pass including 
the lower and the upper limit of quantification (LLOQ & ULOQ) 
concentration.  
Intra day precision and accuracy were determined by analyzing six 
replicates at five different QC levels on the same day. Inter day 
precision and accuracy were determined by analyzing six replicates 
at five different QC levels four consecutive days The acceptance 
criteria for accuracy should within±15% standard deviation to their 
nominal concentrations except for LLOQ, it should be±20 and 
precision should within ≤15% relative standard deviation (RSD) 
except for LLOQ, it should be ≤20%.  
The recovery was calculated by analyzing extracted QC samples at 
three levels (LQC, MQC and HQC) with that of the aqueous 
equivalents, which were having the same concentration of the QC 
samples prepared in the mobile phase without any extraction 
procedure. Similarly, the recovery of the IS was determined by 
comparing the mean peak areas of the extracted QC samples for 
their IS area with the aqueous equivalent’s IS area. The acceptance 
for the recovery was the RSD of the areas obtained for extracted and 
aqueous equivalents should be ≤15% individually at each level of QC 
samples and the RSD of the % recoveries for all of QC levels should 
be ≤ 15%. The recovery should be<115% at any level of 
concentration.  
To demonstrate that a method is suitable for a DBS sample to 
quantify an analyte concentration higher than the ULOQ, the dilution 
integrity should be assessed. However, different from whole blood, 
plasma or serum which can be diluted using the same matrix blank 
prior to analysis a DBS itself cannot be diluted.  
A simple approach is to dilute the extracted dilution QC sample 
using one or more of extracted DBS zero samples (containing IS 
only). The diluted QC sample was then analyzed along with the 
calibration standards. The obtained bias from the diluted QCs in six 
replicates should be within±15% of the nominal value and with 
%CV<15%. 
Influence of hematocrit on assay quantitation was measured by 
preparing two different concentrations of gemcitabine at LQC 
and HQC level in whole human blood with varied hematocrit 
values (0.25 and 0.62) for both the QC levels respectively. A 
difference within±15% of the nominal values for the measured 
analyte concentrations from the hematocrit QC samples against a 
calibration standard that was prepared in fresh blood with a 
hematocrit value of 0.43% is acceptable showing a negligible 
hematocrit effect.  
Dried blood spotting sample volume variability was evaluated by 
spotting volumes 20 µl and 30 µl at LQC and HQC levels. These QC 
samples were analysed against calibration standards prepared using 
50 µl of blood volume. A difference within±15% of the nominal values 
would suggest no significant effect of blood volume on sensitivity. 
Stability experiments were conducted to evaluate the gemcitabine 
stability at different storage and processing conditions. Auto 
sampler stability was evaluated by storing extracted QC samples in 
the auto sampler (4 °C) for 72 hours. Post preparative stability was 
evaluated to show that the integrity of the entire run is maintained, 
if reinjected after a specified number of hours.  
This was performed by reinjecting an accepted analytical run, 
usually a precision and accuracy batch. Long-term stability of 
gemcitabine in human blood was established by analyzing DBS cards 
stored at room temperature for specific durations, The 
concentrations of the stored samples were determined using freshly 
made STDs and QCs. Samples were considered stable, if assay values 
were within the acceptance limits of accuracy should be±15% of 
their nominal concentrations and precision should be ≤15 RSD.  
RESULTS  
Mass spectrometry 
Mass parameters were tuned in both “+” Ve and “–“Ve ionization 
modes. The more reproducible area was achieved in positive 
polarity mode for both analyte and IS. The data from MRM mode was 
considered to obtain better selectivity. Protonated [M+H]+form of 
each analyte and IS was the parent ion in the Q1 spectrum. The same 
was used as the precursor ion to obtain Q3 production spectra. The 
most sensitive mass transitions were monitored from m/z 264.20 to 
112 for gemcitabine and from 237.30 to 194.1 m/z for 
Carbamazepine. 
Method development  
Separation was attempted using various combinations of Methanol, 
acetonitrile and buffer with varying contents of each component on 
different columns; C8 and C18 
As shown in fig. 2A, no significant direct interference in the blank 
was observed from endogenous substances in drug–free human 
blood at the retention time of the analyte and the IS. Similarly, fig. 2B 
shows the absence of direct interference from the IS to the MRM 
channel of the analyte. Fig. 2C depicts a representative ion–
chromatogram for the LLOQ sample (5.0 ng/ml).  
of different makes. The use of 2 mM 
ammonium acetate buffer (pH 6.4±0.1) was useful in achieving 
optimum reproducible response.  
Mobile phase consisting of methanol and 2 mM ammonium acetate 
buffer (pH 6.4±0.1) was found to be suitable, at which the analytes 
were protonated and well separated. BDS Hypersil C18 (Thermo 
scientific; 100 mm X 4.6 mm, 5 µm) gave a good peak shape and 
response. The mobile phase drawn at a flow rate of 0.5 mL/min gave 
shorter run time of the chromatography. A simple mixture of 
acetonitrile: water (90:10v/v) as an extraction solvent proved to be 
rugged and provided the cleanest samples. 
A suitable internal standard must mimic the analyte during 
extraction and compensate for any analyte on the column. After 
checking with several available compounds, finally carbamazepine 
was found to be the best to serve as an internal standard. 
Selectivity  
The selectivity of the method was examined by analyzing extracted 
dried blank human blood samples from six different sources. Typical 
chromatograms of extracted blank human blood spot (fig. 2A) and 
an extract spiked only with the IS (fig. 2B).  
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Fig. 2: Typical chromatogram of gemcitabine (left panel) and IS 
(right panel) in human blank plasma [A], plasma spiked with 
internal standard [B] and lower limit of quantification sample 
along with IS [C] 
 
Recovery 
Acetonitrile: water (90:10v/v) mixture as an extraction solvent 
proved to be rugged and provided the cleanest samples. The % 
recovery was more than 83.5% and the CV (%) was<4.0%. 
Matrix effect and sensitivity 
There was no significant matrix effect observed in all six lots of human 
blood for the analyte at low and high QC level concentrations. The 
precision and accuracy for gemcitabine at LQC concentration were 
found to be 12.01% and 99.07%, and at HQC level they were 11.1% 
and 93.67%, respectively, the %CV of the IS-normalized matrix factor 
was less than 12.0%. Results revealed that no significant matrix effect 
was observed in all the six batches of human blood. 
The lowest limit of reliable quantification for the analytes was set at 
the concentration of the LLOQ. The precision and accuracy of analyte 
at 5.0 ng/ml concentration was found to be 2.66% and 99.8%, 
respectively. 
Linearity, Precision and accuracy  
The ten-point calibration curve was found to be linear over the 
concentration range of 5-5000 ng/ml for gemcitabine. After 
comparing the weighting factor models at none, 1/X and 1/X2,the 
linear regression equation with weighting factor 1/X2
Dilution integrity was accessed at a concentration approximately 1.6 
times of ULOQ. 50 µl of whole blood containing gemcitabine at a 
concentration of 8000 ng/ml was spotted on each circle of FTA DMPK-
A cards. The samples were dried and extracted as previously 
described. The extracts were diluted 2x and 4x using blank DBS spots 
containing internal standard similarly extracted in the same batch. 
 
Table 1: Intra and inter day precession and accuracy for the determination of gemcitabine in spiked human blood 
 of the analyte 
to the internal standard concentration found to produce the best fit 
for the concentration–detector response relationship. The mean 
correlation coefficient of the weighted calibration curves generated 
during the validation was ≥ 0.99. 
The results for intra–day and inter–day precision and accuracy are 
summarized in table 1. The intra–day and inter day precision 
deviation values were all within 15% of the relative standard 
deviation (RSD) at low, middle 1, middle 2 and high quality control 
levels, whereas within 20% at LLOQ QCs level. The intra–day and 
inter–day accuracy deviation values were all within 100±15% of the 
actual values at low, middle 1, middle 2 and high quality control 
levels, whereas within 100±20% at LLOQ QCs level. The results 
revealed good precision and accuracy. 
Dilution integrity 
Sample Conc Added 
(ng/ml) 
Intra-day Precision and Accuracy 
(n=12; 6 from each batch) 
Inter-day Precision and Accuracy 















LLOQ 5.2 5.230±0.216  4.14 100.5 5.256±0.245 4.67 101.0 
LQC 14.5 16.178±0.750 4.64 111.5 16.0453±0.695 4.34 110.6 
MQC1 245.1 233.429±10.717 4.59 96.6 233.635±7.730 3.31 96.7 
MQC2 1050.0 1200.878±45.885  3.82  114.3 1144.982±65.884 5.75 109.0 
HQC 4200.0 4101.566±179.257  4.37  97.6 4019.897±199.846 4.97 95.7 
 
.Stability studies 
Table 2 shows the Autosampler stability of the sample extracts 
stored at 4 °C for 72 hours. Post preparative stability for 62 h. 
Gemcitabine remained stable in DBS when stored for 3 months at 
room temperature. 
Effect of blood volume spotted on the DBS card 
Gemcitabine concentration from spot volumes of 20, and 30 µl was 
evaluated for demonstrating whether an exact spotting volume is 
required for accurate results. Table 3 shows both the spot volumes 
were comparable to those 50 µl with %CV of ≤11.8 and within 100.2 
to 107% of nominal values. 
Effect of hematocrit 
Hematocrit values differ in cancer patients so attempts were made 
to establish the effect of hematocrit on DBS analysis. Table 4 shows 
that results with different hematocrit values ranging from 0.25% 
and 0.62% are within the acceptable limit. 
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Table 2: It shows stability data for gemcitabine in human blood 




Auto Sampler 14.5 a 0.132±0.001 1.23 98.0 
4200 7.092±0.038 0.54 91.8 
Re injection 14.5 b 13.700±0.876 6.40 102.5 
4200 3875.433±202.401 5.22 101.4 
Long term 14.5 c 15.969±0.933 5.84 110.1 
4200 4060.011±247.316 6.09 96.6 
aafter 72h at 2–8 °C; b after 62 h at 2–8 °C; c after 90days at room temperature 
 
Table 3: It shows effect of spotting volume on accuracy and precision of gemcitabine from extracted human blood 






1 20 14.5 15.466±1.817 11.75 106.6 
  4200.0 4278.583±191.414 4.47 101.8 
2 30 14.5 14.525±1.231 8.48 100.2 
  4200.0 4414.013±201.008 4.55 105.1 
 
Table 4: it shows the effect of hematocrit on accuracy and precision of gemcitabine from extracted human blood 






1 0.25 14.5 13.485±0.874 6.49 93.0 
  4200.0 4080.393±194.956 4.78 97.1 
2 0.62 14.5 14.959±0.847 5.67 103.1 
  4200.0 4008.649±183.023 4.57 95.4 
 
Stability of gemcitabine in whole blood in presence and absence 
of THU: Comparision to DBS 
Degradation of gemcitabine was observed in whole blood samples in 
an absence of THU. More than 22% of gemcitabine was deaminated 
in 3hr time. Fig. 3a shows presence of THU is needed for the exact 
quantitation of gemcitabine in plasma. 
Interestingly, on the other hand the samples prepared on DBS cards 
with or without THU didn’t make any effect in quantifying 
gemcitabine. Fig. 3b shows that gemcitabine was stable on DBS 
cards for nearly 90days. 
 
 
Fig. 3a: It shows Whole Blood Stability of gemcitabine in 
presence and absence of THU 
 
DISCUSSION 
In summary, we have developed a simple protein precipitation 
extraction in conjunction with a five minute LC methods which 
provided the efficiency required for a high throughput assay. 
Compared with the proposed methods (Free man,KB et al. [11] 18 
min, Keith,B et al. [13] 17 min, Yilmaz,B et al. [14] 20 min, Tashinga 
E. Bapiro et al. [21], 15 min) this method has the shortest run time. 
Lin,NM et al. [15] have used a higher volume of plasma(1 ml), R Honey 
well et al. [18] followed a liquid-liquid extraction technique with two 


























Fig. 3b: It shows Whole Blood Stability of gemcitabine in 
presence and absence of THU on DBS 
 
Both these methods were able to quantify dfdu with a limit of 
quantification of 50 ng/ml. There is only a single method proposed 
with a shorter run time of 1.5 min proposed by Chester Bowen et al. 
[23]. But the limitation of this method was a tedious derivatization 
process with densyl chloride followed by a liquid liquid extraction of 
densyl derivatives from plasma. In the developed method we have 
used a very small volume of blood on DBS cards, followed by a 
simple protein precipitation extraction to get a sensitivity of 5 
ng/ml, the lowest concentration reported compared to the 
published literature, except for the method proposed by Yan xu et al. 
[20], where they used a solid phase extraction technique to achieve a 
sensitivity of 5 ng/ml with 15 min run time. Tetrahydrouridine a 
cytidine deaminase inhibitor is not a stable compound and need to 
be added into sampling device at day of sampling, making it more 
difficult for the clinical staff to prepare it fresh each time and 
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pipetting out into sampling tubes. Experiments shown that the need 
of THF as stabiliser to inhibit the cytidine deaminase activity in 
blood or plasma. A degradation of parent compound to 22% was 
observed in negative control samples (without THF in blood 
samples) in 2hr. The method optimised by D'Arienzo CJ et al. [34] for 
stabilisation of prodrugs on DBS cards without addition of esterase 
inhibitors was an important reference for the method development 
in this study. The long term stability data for gemcitabine on DBS 
cards without THU proves that this novel method can be applied for 
sample collection and storage in analyzing the clinic samples.  
CONCLUSION 
The proposed method has several advantages like avoiding THU in 
blood tubes potentially minimises errors in the clinic during sample 
collection, reduces biohazard risks and experiments proved that 
samples are stable at room temperature for longer times can 
circumvent the need of freezers compared to other blood based 
samples. Despite that the method is simple and rapid with a short 
run time of 5 min compared to the published methods. This method 
can be applied in clinic for therapeutic drug monitoring and also in 
bioequivalence studies. 
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